Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04533542 · ClinicalTrials.gov registry record
Nicotine Vapor Specific Sensory Measurement
A clinical trial, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- 42
- Enrollment target
NCT04533542: Completed study, sponsored by Roswell Park Cancer Institute.
NCT04533542 is a clinical trial that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04533542 has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
This trial aims to develop reliable and valid measures of sensory experiences unique to e-cigarette use. Regardless of whether flavorings show evidence of toxicity in a biological sense, they may nonetheless increase harm by other means, such as increasing appeal, decreasing risk perceptions, or masking harshness or irritation that might lead users to discontinue use.
Primary Outcome
Will be assessed by product evaluation scale - Scale consists of 22 questions with #1 = Not at all - 7 = Extremely
Interventions
- OTHER Questionnaire Administration
- OTHER Measurement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-03-10 |
| Est. Completion | 2023-03-07 |
What the finished NCT04533542 record still lists
NCT04533542 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Questionnaire Administration is the first listed.
NCT04533542 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04533542 about?
NCT04533542 is a clinical study titled "Nicotine Vapor Specific Sensory Measurement". This trial aims to develop reliable and valid measures of sensory experiences unique to e-cigarette use. Regardless of whether flavorings show evidence of toxicity in a biological sense, they may nonetheless increase harm by other means, such as increasing appeal, decreasing risk perceptions, or mas...
What is the current status of trial NCT04533542?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2021-03-10. Estimated completion is 2023-03-07.
What interventions are being tested in trial NCT04533542?
The interventions under investigation include: Questionnaire Administration (OTHER), Measurement (OTHER).
Who is sponsoring clinical trial NCT04533542?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI